CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

CNS Pharmaceuticals, Inc. CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.

The trial compared Berubicin to Lomustine, a current standard of care in recurrent or progressive GBM.

This analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint.

Additionally, patients experienced no cardiotoxicity, a risk that curtails the use of other anthracyclines, and the safety profile continues to be favorable in this patient population.

The company says the data appear comparable to Lomustine in important clinically relevant endpoints, including overall survival (OS) and progression-free survival (PFS) across all patients treated with Berubicin.

“Because of the cardiotoxicity associated with other anthracyclines,” said Sandra Silberman, chief medical officer of CNS Pharmaceuticals, “the fact that this study showed no cardiotoxicity with Berubicin, even in those receiving the drug for over a year, suggests Berubicin could be a valuable recourse for patients with recurrent or progressive cancers.”

“Berubicin also did not exhibit the pulmonary toxicity or the thrombocytopenia associated with Lomustine, suggesting it could be a way for patients to avoid those side effects during treatment. Furthermore, its primary mechanism of action, topoisomerase II inhibition, is agnostic to specific tumor histology, making it a potentially more generalizable therapy,” she added.

As of Feb. 26, 2025, the company’s current cash position has increased to $14 million. Based on current projections, management believes the current cash on hand is sufficient to fund operations into 2026.

Price Action: CNSP stock is down 59.9% at $1.37 at last check Tuesday.

Read Next:

• Generac Poised To Benefit From Blackouts, Declining Grid Reliability: BofA Analyst

Photo: Shutterstock